360° SearchNetwork Hot Spots Trends Time Series

Altor BioScience Corp

Type: Company

Name: Altor BioScience Corp

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Florida falls to 29th in venture funding, 2nd lowest rank since 1995

Orlando-based Doccaster Inc. received $20,000 from an investment firm earlier this year ? slim pickings in the world of venture capital. But the high-tech startup isn't complaining, not when many Florida companies can't seem to raise a dime this year ... [Published Orlando Sentinel - Apr 23 2013]

Entities: National Venture Capital Association, Altor BioScience Corp, West Melbourne (United States), Venture Capital

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2013

Research and Markets has announced the addition of the report to their offering. '', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Non Muscle Invasive Bladder Cancer ... [Published Individual.com - Apr 22 2013]

Entities: Bladder Cancer, Altor BioScience Corp, Spectrum Pharmaceuticals Inc, Therapeutics, Phase III

Quotes

...less capital than it has been investing now for several years," said John Taylor, research chief of the National Venture Capital Association. "We expect these overall trends to continue until exits [IPOs and acquisitions] increase, and subsequent fundraising activities pick up, and dollars start to flow back into more venture funds."

Florida falls to 29th in venture funding, 2nd lowest rank since 1995 [Published Orlando Sentinel - Apr 23 2013]

Research and Markets has announced the addition of the report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Scope - A snapshot of the global therapeutic scenario for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). - A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Development - Spectrum Pharmaceuticals Inc. - Altor BioScience Corporation - Telormedix SA - Viventia Biotechnologies Inc. Drug Profiles - apaziquone - apaziquone - TMX-101 - oportuzumab monatox - ALT-803 - TD-6989 - TD-3633 - CEL-031 Featured News & Press Releases - Sep 11, 2012: Cold Genesys Announces Agreement With FDA On Special Protocol Assessment Of Phase IIPhase II IIIIII Pivotal Trial Of Bladder Cancer Candidate - Apr 18, 2012: Celek Pharma To Present Recent Progress On Anticancer Drug, CEL-031, At NCI's Investor Forum - Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials - Apr 02, 2012: Connaught Strain Of BCG Shows Potential To Treat Non-Muscle-Invasive Bladder Cancer In Phase III Study - Mar 19, 2012: Telormedix's TMX-101 Exhibits High Safety In Phase IPhase I II TrialII Trial For Non-Muscle Invasive Bladder Cancer - Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium Companies Mentioned - Altor BioScience Corporation - Spectrum Pharmaceuticals Inc. - Telormedix SA - Viventia Biotechnologies Inc. For more information visit CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=5hxktp)"

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2013 [Published Individual.com - Apr 22 2013]

sort by: Date \| Relevance
Research and Markets: Non Muscle Invasive Bladd... [Published Business Wire - Apr 22 2013]
Research and Markets: Cytomegalovirus (HHV-5) I... [Published Business Wire - Apr 17 2013]